Pfizer Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
May 17, 2024 at 10:12 am EDT
Share
Pfizer Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 5,466.3 million compared to INR 5,726.4 million a year ago. Revenue was INR 6,217.6 million compared to INR 6,040.2 million a year ago. Net income was INR 1,788.6 million compared to INR 1,296.5 million a year ago. Basic earnings per share from continuing operations was INR 22.33 compared to INR 28.34 a year ago. Diluted earnings per share from continuing operations was INR 22.33 compared to INR 28.34 a year ago.
For the full year, sales was INR 21,931.7 million compared to INR 24,247.6 million a year ago. Revenue was INR 23,736.8 million compared to INR 25,258.1 million a year ago. Net income was INR 5,513.3 million compared to INR 6,239.3 million a year ago. Basic earnings per share from continuing operations was INR 120.51 compared to INR 136.38 a year ago. Diluted earnings per share from continuing operations was INR 120.51 compared to INR 136.38 a year ago.
Pfizer Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company has its own manufacturing facility at Goa. The Company has various independent contract/third party manufacturers based across India. Its product portfolio includes vaccine, anti-infectives, cardiac, pain, maternal nutrition, gastrointestinal, contraceptives, anti-inflammatory, nutrition and immunity, and respiratory. The Company's vaccine business is focused on Prevenar 13, a pneumococcal conjugate vaccine that is administered to infants who are six weeks and older as part of primary vaccination, toddlers, adolescents, adults, and elderly population. Its inflammation and immunology portfolio includes two advanced therapies, which cater to patients suffering from diseases related to chronic immune system such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis and ulcerative colitis.